Entrada Therapeutics, ENTR-601-45, Duchenne Muscular Dystrophy, DMD, ELEVATE-45-201, Phase 1/2 Clinical Trial, Exon 45 Skipping, Dystrophin Production, Genetic Medicines

BOSTON, October 14, 2026 Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced positive topline results from Cohort 1 of its Phase...